{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:44:39Z","timestamp":1775763879950,"version":"3.50.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00393-018-0588-1","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T11:11:03Z","timestamp":1548414663000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evidenzbasierte Therapieempfehlungen f\u00fcr das famili\u00e4re Mittelmeerfieber","Evidence-based treatment recommendations for familial Mediterranean fever"],"prefix":"10.1007","volume":"78","author":[{"given":"T.","family":"Kallinich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Neudorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. T.","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Weseloh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0002-9343(67)90167-2","volume":"43","author":"E Sohar","year":"1967","unstructured":"Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227\u2013253","journal-title":"Am J Med"},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00393-017-0265-9","volume":"76","author":"T Kallinich","year":"2017","unstructured":"Kallinich T, Orak B, Wittkowski H (2017) Role of genetics in familial Mediterranean fever. Z\u00a0Rheumatol 76:303\u2013312. https:\/\/doi.org\/10.1007\/s00393-017-0265-9","journal-title":"Z Rheumatol"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S et\u00a0al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644\u2013651. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208690","journal-title":"Ann Rheum Dis"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJM197410312911803","volume":"291","author":"D Zemer","year":"1974","unstructured":"Zemer D et\u00a0al (1974) A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N\u00a0Engl J Med 291:932\u2013934. https:\/\/doi.org\/10.1056\/NEJM197410312911803","journal-title":"N Engl J Med"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJM197410312911804","volume":"291","author":"CA Dinarello","year":"1974","unstructured":"Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N\u00a0Engl J Med 291:934\u2013937. https:\/\/doi.org\/10.1056\/NEJM197410312911804","journal-title":"N Engl J Med"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.7326\/0003-4819-81-6-792","volume":"81","author":"RC Goldstein","year":"1974","unstructured":"Goldstein RC, Schwabe AD (1974) Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 81:792\u2013794","journal-title":"Ann Intern Med"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","volume":"314","author":"D Zemer","year":"1986","unstructured":"Zemer D et\u00a0al (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N\u00a0Engl J Med 314:1001\u20131005. https:\/\/doi.org\/10.1056\/NEJM198604173141601","journal-title":"N Engl J Med"},{"key":"588_CR8","first-page":"e474","volume":"119","author":"T Kallinich","year":"2007","unstructured":"Kallinich T et\u00a0al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatr Electron Pages 119:e474\u2013483. https:\/\/doi.org\/10.1542\/peds.2006\u20131434","journal-title":"Pediatr Electron Pages"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","volume":"43","author":"V Hentgen","year":"2013","unstructured":"Hentgen V et al (2013) Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 43:387\u2013391. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.04.011","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR10","first-page":"15","volume":"4","author":"C Diesinger","year":"2017","unstructured":"Diesinger C, Schriever J (2017) Colchicin \u2013 gut informieren, sicher dosieren. Bull Arzneimittelsicherh 4:15\u201323","journal-title":"Bull Arzneimittelsicherh"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/BTT.S102954","volume":"10","author":"J Hilst van der","year":"2016","unstructured":"van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a\u00a0systematic review of the literature. Biol : Targets Ther 10:75\u201380. https:\/\/doi.org\/10.2147\/BTT.S102954","journal-title":"Biol : Targets Ther"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a\u00a0randomized trial. Ann Intern Med 157:533\u2013541. https:\/\/doi.org\/10.7326\/0003-4819-157-8-201210160-00003","journal-title":"Ann Intern Med"},{"key":"588_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","volume":"69","author":"I Ben-Zvi","year":"2017","unstructured":"Ben-Zvi I et al (2017) Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 69:854\u2013862. https:\/\/doi.org\/10.1002\/art.39995","journal-title":"Arthritis Rheumatol"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F Benedetti De","year":"2018","unstructured":"De Benedetti F et\u00a0al (2018) Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N\u00a0Engl J Med 378:1908\u20131919. https:\/\/doi.org\/10.1056\/NEJMoa1706314","journal-title":"N Engl J Med"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13506129908993281","volume":"6","author":"A Livneh","year":"1999","unstructured":"Livneh A et\u00a0al (1999) MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6:1\u20136","journal-title":"Amyloid"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.ejhg.5200303","volume":"7","author":"M Shohat","year":"1999","unstructured":"Shohat M et al (1999) Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 7:287\u2013292. https:\/\/doi.org\/10.1038\/sj.ejhg.5200303","journal-title":"Eur J Hum Genet"},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"The French FMF Consortium","year":"1997","unstructured":"The French FMF Consortium (1997) A candidate gene for familial mediterranean fever. Nat Genet 17:25\u201331. https:\/\/doi.org\/10.1038\/ng0997-25","journal-title":"Nat Genet"},{"key":"588_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0092-8674(00)80539-5","volume":"90","author":"The International FMF Consortium","year":"1997","unstructured":"The International FMF Consortium (1997) Ancient missense mutations in a\u00a0new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797\u2013807","journal-title":"Cell"},{"key":"588_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajmg.1438","volume":"102","author":"A Kogan","year":"2001","unstructured":"Kogan A et\u00a0al (2001) Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a\u00a0perceptible biological advantage for the carrier state. Am J Med Genet 102:272\u2013276","journal-title":"Am J Med Genet"},{"key":"588_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-015-0252-7","volume":"10","author":"I Ben-Zvi","year":"2015","unstructured":"Ben-Zvi I et al (2015) Familial Mediterranean fever without MEFV mutations: a\u00a0case-control study. Orphanet J Rare Dis 10:34. https:\/\/doi.org\/10.1186\/s13023-015-0252-7","journal-title":"Orphanet J Rare Dis"},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.rbre.2015.08.019","volume":"56","author":"MT Terreri","year":"2016","unstructured":"Terreri MT et\u00a0al (2016) Guidelines for the management and treatment of periodic fever syndromes familial Mediterranean fever. Rev Bras Reumatol 56:37\u201343. https:\/\/doi.org\/10.1016\/j.rbre.2015.08.019","journal-title":"Rev Bras Reumatol"},{"key":"588_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010893.pub2","author":"B Wu","year":"2015","unstructured":"Wu B, Xu T, Li Y, Yin X (2015) Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010893.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00296-015-3408-9","volume":"36","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E, Erer B, Ozen S, Ben-Chetrit E (2016) Efficacy and safety of treatments in Familial Mediterranean fever: a\u00a0systematic review. Rheumatol Int 36:325\u2013331. https:\/\/doi.org\/10.1007\/s00296-015-3408-9","journal-title":"Rheumatol Int"},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/bmj.2.6090.808","volume":"2","author":"M Levy","year":"1977","unstructured":"Levy M, Eliakim M (1977) Long-term colchicine prophylaxis in familial Mediterranean fever. BMJ 2:808","journal-title":"BMJ"},{"key":"588_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0022-3476(78)81107-X","volume":"93","author":"TJ Lehman","year":"1978","unstructured":"Lehman TJ, Peters RS, Hanson V, Schwabe A (1978) Long-term colchicine therapy of familial Mediterranean fever. J\u00a0Pediatr 93:876\u2013878","journal-title":"J Pediatr"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0022-3476(05)80667-5","volume":"116","author":"HA Majeed","year":"1990","unstructured":"Majeed HA, Carroll JE, Khuffash FA, Hijazi Z (1990) Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis). J\u00a0Pediatr 116:997\u2013999","journal-title":"J Pediatr"},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF00441519","volume":"148","author":"HA Majeed","year":"1989","unstructured":"Majeed HA, Barakat M (1989) Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr 148:636\u2013641","journal-title":"Eur J Pediatr"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/art.1780340806","volume":"34","author":"D Zemer","year":"1991","unstructured":"Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973\u2013977","journal-title":"Arthritis Rheum"},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/rheumatology\/kex222","volume":"56","author":"AM Knieper","year":"2017","unstructured":"Knieper AM et\u00a0al (2017) Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Baillieres Clin Rheumatol 56:1597\u20131606. https:\/\/doi.org\/10.1093\/rheumatology\/kex222","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/art.40344","volume":"70","author":"R Brenner","year":"2018","unstructured":"Brenner R et al (2018) Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatol 70:127\u2013133. https:\/\/doi.org\/10.1002\/art.40344","journal-title":"Arthritis Rheumatol"},{"key":"588_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0049-0172(98)80028-0","volume":"28","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28:48\u201359","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/GIM.0b013e3182060456","volume":"13","author":"M Shohat","year":"2011","unstructured":"Shohat M, Halpern GJ (2011) Familial Mediterranean fever\u2014a review. Genet Med 13:487\u2013498. https:\/\/doi.org\/10.1097\/GIM.0b013e3182060456","journal-title":"Genet Med"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-017-0609-1","volume":"12","author":"A Corsia","year":"2017","unstructured":"Corsia A et\u00a0al (2017) A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis 12:54. https:\/\/doi.org\/10.1186\/s13023-017-0609-1","journal-title":"Orphanet J Rare Dis"},{"key":"588_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00296-015-3413-z","volume":"36","author":"B Erer","year":"2016","unstructured":"Erer B, Demirkaya E, Ozen S, Kallinich T (2016) What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int 36:483\u2013487. https:\/\/doi.org\/10.1007\/s00296-015-3413-z","journal-title":"Rheumatol Int"},{"key":"588_CR35","first-page":"355","volume":"15","author":"D Buskila","year":"1997","unstructured":"Buskila D et\u00a0al (1997) Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 15:355\u2013360","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR36","first-page":"S96","volume":"27","author":"B Makay","year":"2009","unstructured":"Makay B, Unsal E, Arslan N, Varni JW (2009) Health-related quality of life of school-age children with familial Mediterranean fever. Clin Exp Rheumatol 27:S96\u2013S101","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00296-009-1334-4","volume":"31","author":"SM Deger","year":"2011","unstructured":"Deger SM et al (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31:623\u2013628. https:\/\/doi.org\/10.1007\/s00296-009-1334-4","journal-title":"Rheumatol Int"},{"key":"588_CR38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00296-012-2622-y","volume":"33","author":"A Giese","year":"2013","unstructured":"Giese A et\u00a0al (2013) Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a\u00a0study evaluating the effect of disease severity and country of residence. Rheumatol Int 33:1713\u20131719. https:\/\/doi.org\/10.1007\/s00296-012-2622-y","journal-title":"Rheumatol Int"},{"key":"588_CR39","first-page":"958","volume":"17","author":"S Sahin","year":"2013","unstructured":"Sahin S et al (2013) Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci 17:958\u2013963","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"588_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/(SICI)1096-8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R","volume":"75","author":"E Pras","year":"1998","unstructured":"Pras E et\u00a0al (1998) Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 75:216\u2013219","journal-title":"Am J Med Genet"},{"key":"588_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semarthrit.2005.02.002","volume":"35","author":"A Mor","year":"2005","unstructured":"Mor A et\u00a0al (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35:57\u201364. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.02.002","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR42","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrrheum.2012.54-c1","volume":"8","author":"G Kalkan","year":"2012","unstructured":"Kalkan G, Demirkaya E, Ozen S (2012) Severity scoring system for paediatric FMF. Nat Rev Rheumatol 8:621. https:\/\/doi.org\/10.1038\/nrrheum.2012.54-c1","journal-title":"Nat Rev Rheumatol"},{"key":"588_CR43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2015-208671","volume":"75","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E et\u00a0al (2016) Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75:1051\u20131056. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208671","journal-title":"Ann Rheum Dis"},{"key":"588_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrrheum.2016.55","volume":"12","author":"HJ Lachmann","year":"2016","unstructured":"Lachmann HJ, Brogan PA (2016) Autoinflammation: When is familial Mediterranean fever \u2018severe\u2019? Nat Rev Rheumatol 12:256\u2013258. https:\/\/doi.org\/10.1038\/nrrheum.2016.55","journal-title":"Nat Rev Rheumatol"},{"key":"588_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/ard.2010.132613","volume":"70","author":"M Piram","year":"2011","unstructured":"Piram M et al (2011) A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis 70:309\u2013314. https:\/\/doi.org\/10.1136\/ard.2010.132613","journal-title":"Ann Rheum Dis"},{"key":"588_CR46","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/annrheumdis-2013-204719","volume":"73","author":"S Ozen","year":"2014","unstructured":"Ozen S et\u00a0al (2014) FMF50: a\u00a0score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73:897\u2013901. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204719","journal-title":"Ann Rheum Dis"},{"key":"588_CR47","first-page":"129","volume":"34","author":"D Konukbay","year":"2016","unstructured":"Konukbay D et\u00a0al (2016) A novel assessment tool for clinical care of patients with autoinflammatory disease: juvenile autoinflammatory disease multidimensional assessment report. Clin Exp Rheumatol 34:129\u2013135","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/kei279","volume":"45","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ et\u00a0al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Baillieres Clin Rheumatol 45:746\u2013750. https:\/\/doi.org\/10.1093\/rheumatology\/kei279","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/ard.61.1.79","volume":"61","author":"C Korkmaz","year":"2002","unstructured":"Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79\u201381","journal-title":"Ann Rheum Dis"},{"key":"588_CR50","first-page":"509","volume":"21","author":"A Duzova","year":"2003","unstructured":"Duzova A et al (2003) Role of A\u2011SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509\u2013514","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clinbiochem.2016.11.008","volume":"50","author":"K Stankovic Stojanovic","year":"2017","unstructured":"Stankovic Stojanovic K et al (2017) Concordance between CRP and SAA in familial mediterranean fever during attack-free period: a study of 218 patients. Clin Biochem 50:206\u2013209. https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.11.008","journal-title":"Clin Biochem"},{"key":"588_CR52","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1002\/art.39784","volume":"68","author":"F Gohar","year":"2016","unstructured":"Gohar F et\u00a0al (2016) Correlation of secretory activity of neutrophils with genotype in patients with familial Mediterranean fever. Arthritis Rheumatol 68:3010\u20133022. https:\/\/doi.org\/10.1002\/art.39784","journal-title":"Arthritis Rheumatol"},{"key":"588_CR53","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/ard.2009.114363","volume":"69","author":"T Kallinich","year":"2010","unstructured":"Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D (2010) Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 69:677\u2013682. https:\/\/doi.org\/10.1136\/ard.2009.114363","journal-title":"Ann Rheum Dis"},{"key":"588_CR54","first-page":"S113","volume":"33","author":"M Lieber","year":"2015","unstructured":"Lieber M et al (2015) Increased serum concentrations of neutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations. Clin Exp Rheumatol 33:S113\u2013S116","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR55","first-page":"S156","volume":"33","author":"S Yesilkaya","year":"2015","unstructured":"Yesilkaya S et\u00a0al (2015) Development of a\u00a0medication adherence scale for familial Mediterranean fever (MASIF) in a\u00a0cohort of Turkish children. Clin Exp Rheumatol 33:S156\u2013S162","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR56","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/1756-185X.12374","volume":"20","author":"MA Melikoglu","year":"2017","unstructured":"Melikoglu MA, Senel K (2017) Non-response to colchicine in familial Mediterranean fever should be identified accurately. Int J Rheum Dis 20:2118\u20132121. https:\/\/doi.org\/10.1111\/1756-185X.12374","journal-title":"Int J Rheum Dis"},{"key":"588_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-016-0980-7","volume":"18","author":"A Polat","year":"2016","unstructured":"Polat A et al (2016) Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever\u2014a randomized controlled noninferiority trial. Arthritis Res Ther 18:85. https:\/\/doi.org\/10.1186\/s13075-016-0980-7","journal-title":"Arthritis Res Ther"},{"key":"588_CR58","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(70)92206-3","volume":"2","author":"SL Wallace","year":"1970","unstructured":"Wallace SL, Ertel NH (1970) Occupancy approach to colchicine dosage. Lancet 2:1250\u20131251","journal-title":"Lancet"},{"key":"588_CR59","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/clpt.1993.161","volume":"54","author":"ON Chappey","year":"1993","unstructured":"Chappey ON et\u00a0al (1993) Colchicine disposition in human leukocytes after single and multiple oral administration. Int J Clin Pharmacol Ther 54:360\u2013367","journal-title":"Int J Clin Pharmacol Ther"},{"key":"588_CR60","first-page":"616","volume":"31","author":"A Fradkin","year":"1995","unstructured":"Fradkin A, Yahav J, Zemer D, Jonas A (1995) Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci 31:616\u2013620","journal-title":"Isr J Med Sci"},{"key":"588_CR61","first-page":"318","volume":"65","author":"M Lidar","year":"2007","unstructured":"Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318\u2013324","journal-title":"Neth J Med"},{"key":"588_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00296-017-3823-1","volume":"38","author":"S Haj Yahia","year":"2018","unstructured":"Haj Yahia S, Zvi BI, Livneh A (2018) Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a\u00a0series of six patients. Rheumatol Int 38:141\u2013147. https:\/\/doi.org\/10.1007\/s00296-017-3823-1","journal-title":"Rheumatol Int"},{"key":"588_CR63","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.30389","volume":"63","author":"RA Terkeltaub","year":"2011","unstructured":"Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW (2011) Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors. Arthritis Rheum 63:2226\u20132237. https:\/\/doi.org\/10.1002\/art.30389","journal-title":"Arthritis Rheum"},{"key":"588_CR64","volume-title":"Which definition should be used to determine colchicine resistance in patients with familial mediterranean fever?","author":"A Erden","year":"2017","unstructured":"Erden A, Deniz Batu E, Alper S, Emine Sonmez H, Armagan B, Demir S, F\u0131rat E, Bilginer Y, Apras Bilgen S, Karadag O, Kalyoncu U, Kiraz S, Ertenli I, Ozen S, Akdogan A (2017) Which definition should be used to determine colchicine resistance in patients with familial mediterranean fever? ACR\/ARHP Meeting 2017. (Abstract Number 1174)"},{"key":"588_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23446","author":"S Akar","year":"2017","unstructured":"Akar S et al (2017) Nationwide experience with off-label use of interleukin-1 targeting treatment in familial mediterranean fever patients. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.23446","journal-title":"Arthritis Care Res"},{"key":"588_CR66","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A et al (2016) A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol 7:380. https:\/\/doi.org\/10.3389\/fphar.2016.00380","journal-title":"Front Pharmacol"},{"key":"588_CR67","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/14397595.2016.1194510","volume":"27","author":"O Kucuksahin","year":"2017","unstructured":"Kucuksahin O et al (2017) Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol 27:350\u2013355. https:\/\/doi.org\/10.1080\/14397595.2016.1194510","journal-title":"Mod Rheumatol"},{"key":"588_CR68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/acr.23120","volume":"69","author":"S Ozen","year":"2017","unstructured":"Ozen S et al (2017) International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency\/Hyperimmunoglobulinemia D Syndrome. Arthritis Care Res 69:578\u2013586. https:\/\/doi.org\/10.1002\/acr.23120","journal-title":"Arthritis Care Res"},{"key":"588_CR69","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/03009742.2016.1245780","volume":"46","author":"AC Pecher","year":"2017","unstructured":"Pecher AC, Igney-Oertel A, Kanz L, Henes J (2017) Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine. Scand J Rheumatol 46:407\u2013409. https:\/\/doi.org\/10.1080\/03009742.2016.1245780","journal-title":"Scand J Rheumatol"},{"key":"588_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","volume":"38","author":"P Cetin","year":"2015","unstructured":"Cetin P et al (2015) Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation 38:27\u201331. https:\/\/doi.org\/10.1007\/s10753-014-0004-1","journal-title":"Inflammation"},{"key":"588_CR71","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00296-015-3293-2","volume":"35","author":"FK Eroglu","year":"2015","unstructured":"Eroglu FK, Besbas N, Topaloglu R, Ozen S (2015) Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 35:1733\u20131737. https:\/\/doi.org\/10.1007\/s00296-015-3293-2","journal-title":"Rheumatol Int"},{"key":"588_CR72","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","volume":"35","author":"ZB Ozcakar","year":"2016","unstructured":"Ozcakar ZB et al (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Baillieres Clin Rheumatol 35:441\u2013446. https:\/\/doi.org\/10.1007\/s10067-014-2772-2","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR73","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3109\/14397595.2014.987437","volume":"25","author":"O Basaran","year":"2015","unstructured":"Basaran O et al (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25:621\u2013624. https:\/\/doi.org\/10.3109\/14397595.2014.987437","journal-title":"Mod Rheumatol"},{"key":"588_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00296-017-3796-0","volume":"38","author":"K Barut","year":"2018","unstructured":"Barut K et al (2018) Familial Mediterranean fever in childhood: a\u00a0single-center experience. Rheumatol Int 38:67\u201374. https:\/\/doi.org\/10.1007\/s00296-017-3796-0","journal-title":"Rheumatol Int"},{"key":"588_CR75","first-page":"945","volume":"67","author":"S Ozkan","year":"2017","unstructured":"Ozkan S, Atas B (2017) Canakinumab treatment in four children with colchicine resistant familial mediterranean fever. J\u00a0Pak Med Assoc 67:945\u2013947","journal-title":"J Pak Med Assoc"},{"key":"588_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3899\/jrheum.160518","volume":"44","author":"K Laskari","year":"2017","unstructured":"Laskari K et al (2017) Longterm beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever. J\u00a0Rheumatol 44:102\u2013109. https:\/\/doi.org\/10.3899\/jrheum.160518","journal-title":"J Rheumatol"},{"key":"588_CR77","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/rheumatology\/keu474","volume":"54","author":"S Yilmaz","year":"2015","unstructured":"Yilmaz S, Cinar M, Simsek I, Erdem H, Pay S (2015) Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Baillieres Clin Rheumatol 54:564\u2013565. https:\/\/doi.org\/10.1093\/rheumatology\/keu474","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR78","volume-title":"Efficacy and safety of canakinumab in patients with colchicine-resistant familial mediterranean fever, hyper-immunoglobulin d syndrome\/mevalonate kinase deficiency and tnf receptor-associated periodic syndrome","author":"F Benedetti De","year":"2016","unstructured":"De Benedetti F, Jordi A, Ben-Chetrit E, Calvo I, Frenkel J, Gattorno M, Hof man HM, Kasapcopur O, Kon\u00e9-Paut I, Lachmann H, Moutschen M, Ozen S, Quartier P, Simon A, Zeft A, Lheritier K, Speziale A, Junge G (2016) Efficacy and safety of canakinumab in patients with colchicine-resistant familial mediterranean fever, hyper-immunoglobulin d syndrome\/mevalonate kinase deficiency and tnf receptor-associated periodic syndrome. 2016 ACR\/ARHP Annual Meeting ABSTRACT NUMBER: 3205. (40 week results from the pivotal phase 3 umbrella cluster trial)"},{"key":"588_CR79","volume-title":"Genetic phenotypes impacting efficacy and safety of canakinumab in patients with colchicine-resistant FMF, traps and HIDS\/MKD: results from cluster study","author":"F Benedetti De","year":"2017","unstructured":"De Benedetti F, Miettunen P, Kallinich T, Hiorneff G, Brik R, Tomassini A, Yasumi T, Savic S, Foeldvari I, Harel L, Gallizzi R, Speziale A, Junge G, Gattorno M (2017) Genetic phenotypes impacting efficacy and safety of canakinumab in patients with colchicine-resistant FMF, traps and HIDS\/MKD: results from cluster study. 2017 ACR\/ARHP Annual MeetingABSTRACT NUMBER: 1894."},{"issue":"Suppl","key":"588_CR80","first-page":"65","volume":"15","author":"S Ozen","year":"2017","unstructured":"Ozen S, Hofer M, van Der Hilst J, G\u00fcl A, Brogan P, Manna R, Murias S, Karadag O, Gon Y, Vritzali E, Junge G, De De Benedetti F, Ben-Chetrit E (2017) Efficacy, safety, pharmacokinetics and pharmacodynamics of canakinumab in patients with colchicine-resistant fmf: results from the phase 3 cluster trial. Pediatr Rheumatol 15(Suppl):65","journal-title":"Pediatr Rheumatol"},{"key":"588_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","volume":"32","author":"C Kaiser","year":"2012","unstructured":"Kaiser C et al (2012) Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 32:295\u2013299. https:\/\/doi.org\/10.1007\/s00296-011-2096-3","journal-title":"Rheumatol Int"},{"key":"588_CR82","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/14712598.2016.1233963","volume":"16","author":"R Haviv","year":"2016","unstructured":"Haviv R, Hashkes PJ (2016) Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther 16:1425\u20131434. https:\/\/doi.org\/10.1080\/14712598.2016.1233963","journal-title":"Expert Opin Biol Ther"},{"key":"588_CR83","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/1744666X.2017.1313116","volume":"13","author":"H Ozdogan","year":"2017","unstructured":"Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 13:393\u2013404. https:\/\/doi.org\/10.1080\/1744666X.2017.1313116","journal-title":"Expert Rev Clin Immunol"},{"key":"588_CR84","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","volume":"70","author":"EJ Bodar","year":"2011","unstructured":"Bodar EJ et al (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70:2155\u20132158. https:\/\/doi.org\/10.1136\/ard.2011.149922","journal-title":"Ann Rheum Dis"},{"key":"588_CR85","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/rheumatology\/kev111","volume":"54","author":"C Grimwood","year":"2015","unstructured":"Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a\u00a0treatment option for selected TRAPS patients. Baillieres Clin Rheumatol 54:1749\u20131751. https:\/\/doi.org\/10.1093\/rheumatology\/kev111","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/rheumatology\/16.2.102","volume":"16","author":"E Sneh","year":"1977","unstructured":"Sneh E, Pras M, Michaeli D, Shanin N, Gafni J (1977) Protracted arthritis in familial Mediterranean fever. Rheumatol Rehabil 16:102\u2013106","journal-title":"Rheumatol Rehabil"},{"key":"588_CR87","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00003086-198103000-00027","volume":"155","author":"K Kaushansky","year":"1981","unstructured":"Kaushansky K, Finerman GA, Schwabe AD (1981) Chronic destructive arthritis in familial Mediterranean fever: the predominance of hip involvement and its management. Clin Orthop Relat Res 155:156\u2013161","journal-title":"Clin Orthop Relat Res"},{"key":"588_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10067-008-0980-3","volume":"28","author":"T Kasifoglu","year":"2009","unstructured":"Kasifoglu T, Calisir C, Cansu DU, Korkmaz C (2009) The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Baillieres Clin Rheumatol 28:41\u201346. https:\/\/doi.org\/10.1007\/s10067-008-0980-3","journal-title":"Baillieres Clin Rheumatol"},{"key":"588_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0049-0172(97)80007-8","volume":"27","author":"P Langevitz","year":"1997","unstructured":"Langevitz P, Livneh A, Zemer D, Shemer J, Pras M (1997) Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 27:67\u201372","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR90","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3109\/14397595.2016.1162261","volume":"26","author":"T Koga","year":"2016","unstructured":"Koga T, Migita K, Kawakami A (2016) Biologic therapy in familial Mediterranean fever. Mod Rheumatol 26:637\u2013641. https:\/\/doi.org\/10.3109\/14397595.2016.1162261","journal-title":"Mod Rheumatol"},{"key":"588_CR91","first-page":"S114","volume":"25","author":"E Kaplan","year":"2007","unstructured":"Kaplan E et\u00a0al (2007) Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol 25:S114\u2013S117","journal-title":"Clin Exp Rheumatol"},{"key":"588_CR92","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/sarh.2000.16646","volume":"30","author":"HA Majeed","year":"2000","unstructured":"Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30:138\u2013143. https:\/\/doi.org\/10.1053\/sarh.2000.16646","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR93","first-page":"1708","volume":"21","author":"P Langevitz","year":"1994","unstructured":"Langevitz P, Zemer D, Livneh A, Shemer J, Pras M (1994) Protracted febrile myalgia in patients with familial Mediterranean fever. J\u00a0Rheumatol 21:1708\u20131709","journal-title":"J Rheumatol"},{"key":"588_CR94","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.semarthrit.2017.10.008","volume":"47","author":"E Rom","year":"2018","unstructured":"Rom E et\u00a0al (2018) Protracted febrile myalgia syndrome treated with pulse of corticosteroids. Semin Arthritis Rheum 47:897\u2013899. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.008","journal-title":"Semin Arthritis Rheum"},{"key":"588_CR95","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/14397595.2014.882221","volume":"26","author":"R Mercan","year":"2016","unstructured":"Mercan R et\u00a0al (2016) Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Mod Rheumatol 26:458\u2013459. https:\/\/doi.org\/10.3109\/14397595.2014.882221","journal-title":"Mod Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0588-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0588-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0588-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T23:29:56Z","timestamp":1662852596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0588-1"}},"subtitle":["Eine gemeinsame Stellungnahme der Gesellschaft f\u00fcr Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft f\u00fcr Rheumatologie","A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology"],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0588-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"25 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.\u00a0Kallinich gibt folgende m\u00f6gliche Interessenkonflikte an: Honorare von Roche, BMS, Novartis, Sobi; Forschungsf\u00f6rderung von Novartis. N.\u00a0Blank gibt folgende m\u00f6gliche Interessenkonflikte an: Mitarbeit in einem wissenschaftlichen Beirat (Advisory Board) bei Novartis; Vortrags-\/oder Schulungst\u00e4tigkeit f\u00fcr SOBI; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien f\u00fcr SOBI. E.\u00a0Feist hat Beratungshonoraria von AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Swedish Orphan Biovitrum und UCB, sowie Forschungsf\u00f6rderung von BMS, Lilly, Novartis, Pfizer und Roche erhalten. U.\u00a0Kiltz gibt folgende m\u00f6gliche Interessenkonflikte an: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, Chugai, Eli Lilly, Gr\u00fcnenthal, Janssen, MSD, Novartis, Pfizer, Roche und UCB; Forschungsunterst\u00fctzung (\u201eunrestricted grant\u201c) durch AbbVie und Pfizer. U.\u00a0Neudorf gibt folgende m\u00f6gliche Interessenkonflikte an: Durchf\u00fchrung von Studien f\u00fcr Novartis und Chugai, Vortr\u00e4ge f\u00fcr AbbVie. H.\u00a0Wittkowski gibt folgende m\u00f6gliche Interessenkonflikte an: Teilnahme an Ad-Boards: Shire und Novartis; Vortragst\u00e4tigkeit: Shire, CSL-Behring, Novartis, Berg-Apotheke. J.\u00a0Braun gibt folgende m\u00f6gliche Interessenkonflikte an: Durchf\u00fchrung von Studien, Vortr\u00e4ge und Advisory Boards f\u00fcr Novartis, Unterst\u00fctzung von Fortbildungsveranstaltungen durch Novartis, Sobi und Shire. T.\u00a0Braun, C.\u00a0Weseloh und P.T.\u00a0Oommen geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}